http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107540789-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08F220-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08F251-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08F222-38 |
| filingDate | 2017-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107540789-B |
| titleOfInvention | Synthetic method of bioactive derivative bagasse xylan syringate-g-AM |
| abstract | The invention discloses a method for synthesizing bioactive derivative bagasse xylan syringate-g-AM. Using bagasse xylan as a starting material, ammonium persulfate as an initiator, and N , N' -methylenebisacrylamide as a cross-linking agent, the bagasse xylan-g-AM is prepared in an aqueous solution; Bagasse xylan-g-AM is used as raw material, syringic acid is used as esterifying agent, and ammonium persulfate is used as catalyst to prepare bagasse xylan syringate-g in N,N-dimethylacetamide (DMA) solvent ‑AM. The product prepared by the invention is esterified on the basis of grafting, and the synthesized final product bagasse xylan syringate-g-AM not only improves the problem of poor water solubility of bagasse xylan, but also expands its application field. Meanwhile, the introduction of active groups of acrylamide (AM) and syringic acid further enhanced the biological activity of bagasse xylan. |
| priorityDate | 2017-09-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.